About Ocugen, Inc.
https://www.ocugen.comOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
CEO
Shankar Musunuri
Compensation Summary
(Year 2022)
Salary $715,000
Bonus $474,260
Stock Awards $1,635,669
Option Awards $4,825,681
All Other Compensation $12,200
Total Compensation $7,662,810
Industry Biotechnology
Sector Healthcare
Went public December 3, 2014
Method of going public IPO
Full time employees 95
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-09-30 | Reverse | 1:60 |
ETFs Holding This Stock
Summary
Total 21
Showing Top 3 of 21
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 2
Showing Top 2 of 2
Price Target
Target High $6
Target Low $3.5
Target Median $5
Target Consensus $5
Institutional Ownership
BLACKROCK INC.
Shares:17.92M
Value:$33.69M
VANGUARD GROUP INC
Shares:15.22M
Value:$28.62M
MILLENNIUM MANAGEMENT LLC
Shares:4.16M
Value:$7.82M
Summary
% Of Shares Owned 19.51%
Total Number Of Holders 112
Showing Top 3 of 112
Market Cap $465.36 M
52w High $1.96
52w Low $0.52
P/E -8.55
Volume 3.74M
Outstanding Shares 312.32M
About Ocugen, Inc.
https://www.ocugen.comOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.75M ▲ | $19.38M ▲ | $-20.05M ▼ | -1.14K% ▼ | $-0.07 ▼ | $-17.79M ▼ |
| Q2-2025 | $1.37M ▼ | $15.17M ▼ | $-14.74M ▲ | -1.07K% ▼ | $-0.05 ▲ | $-12.87M ▲ |
| Q1-2025 | $1.48M ▲ | $15.98M ▲ | $-15.35M ▼ | -1.04K% ▲ | $-0.05 ▼ | $-13.59M ▼ |
| Q4-2024 | $764K ▼ | $14.6M ▲ | $-13.88M ▼ | -1.82K% ▼ | $-0.05 ▼ | $-13.24M ▼ |
| Q3-2024 | $1.14M | $14.39M | $-12.97M | -1.14K% | $-0.05 | $-12.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $32.56M ▲ | $57.6M ▲ | $54.06M ▲ | $3.53M ▲ |
| Q2-2025 | $27.01M ▼ | $53.59M ▼ | $50.54M ▲ | $3.05M ▼ |
| Q1-2025 | $37.8M ▼ | $64.46M ▼ | $48.55M ▼ | $15.91M ▼ |
| Q4-2024 | $58.51M ▲ | $82.44M ▲ | $52.81M ▲ | $29.63M ▼ |
| Q3-2024 | $38.7M | $61.94M | $21.31M | $40.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.05M ▼ | $-12.92M ▼ | $-86K ▲ | $18.51M ▲ | $5.55M ▲ | $-13.01M ▼ |
| Q2-2025 | $-14.74M ▲ | $-10.73M ▲ | $-88K ▲ | $61K ▲ | $-10.78M ▲ | $-10.77M ▲ |
| Q1-2025 | $-15.35M ▼ | $-19.36M ▼ | $-102K ▼ | $-1.25M ▼ | $-20.71M ▼ | $-19.37M ▼ |
| Q4-2024 | $-13.88M ▼ | $-10.36M ▲ | $-13K ▲ | $30.17M ▼ | $19.82M ▼ | $-10.38M ▲ |
| Q3-2024 | $-12.97M | $-11.27M | $-507K | $34.79M | $23M | $-11.78M |
CEO
Shankar Musunuri
Compensation Summary
(Year 2022)
Salary $715,000
Bonus $474,260
Stock Awards $1,635,669
Option Awards $4,825,681
All Other Compensation $12,200
Total Compensation $7,662,810
Industry Biotechnology
Sector Healthcare
Went public December 3, 2014
Method of going public IPO
Full time employees 95
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-09-30 | Reverse | 1:60 |
ETFs Holding This Stock
Summary
Total 21
Showing Top 3 of 21
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 2
Showing Top 2 of 2
Price Target
Target High $6
Target Low $3.5
Target Median $5
Target Consensus $5
Institutional Ownership
BLACKROCK INC.
Shares:17.92M
Value:$33.69M
VANGUARD GROUP INC
Shares:15.22M
Value:$28.62M
MILLENNIUM MANAGEMENT LLC
Shares:4.16M
Value:$7.82M
Summary
% Of Shares Owned 19.51%
Total Number Of Holders 112
Showing Top 3 of 112